| 1 |
35252007 | Chenodeoxycholic Acid Enhances the Effect of Sorafenib in Inhibiting HepG2 Cell Growth Through EGFR/Stat3 Pathway. | 2022 |
3 |
| 2 |
33770521 | Quiescin sulfhydryl oxidase 1 promotes sorafenib-induced ferroptosis in hepatocellular carcinoma by driving EGFR endosomal trafficking and inhibiting NRF2 activation. | 2021 May |
2 |
| 3 |
34089726 | Sorafenib derivatives-functionalized gold nanoparticles confer protection against tumor angiogenesis and proliferation via suppression of EGFR and VEGFR-2. | 2021 Sep 1 |
1 |
| 4 |
34233013 | Targeting Na+ /K+ -ATPase by berbamine and ouabain synergizes with sorafenib to inhibit hepatocellular carcinoma. | 2021 Nov |
1 |
| 5 |
34655447 | ERK5 signalling pathway is a novel target of sorafenib: Implication in EGF biology. | 2021 Nov |
1 |
| 6 |
32313144 | miR-486-3p mediates hepatocellular carcinoma sorafenib resistance by targeting FGFR4 and EGFR. | 2020 Apr 20 |
3 |
| 7 |
32406930 | An EGFR signature predicts cell line and patient sensitivity to multiple tyrosine kinase inhibitors. | 2020 Nov 1 |
2 |
| 8 |
32504550 | Neratinib decreases pro-survival responses of [sorafenib + vorinostat] in pancreatic cancer. | 2020 Aug |
1 |
| 9 |
33379356 | Y-Box Binding Protein-1 Promotes Epithelial-Mesenchymal Transition in Sorafenib-Resistant Hepatocellular Carcinoma Cells. | 2020 Dec 28 |
1 |
| 10 |
33681180 | Metformin Resensitizes Sorafenib-Resistant HCC Cells Through AMPK-Dependent Autophagy Activation. | 2020 |
4 |
| 11 |
30142009 | Prior exposure of pancreatic tumors to [sorafenib + vorinostat] enhances the efficacy of an anti-PD-1 antibody. | 2019 |
1 |
| 12 |
30552828 | Receptor tyrosine kinase MET as potential target of multi-kinase inhibitor and radiosensitizer sorafenib in HNSCC. | 2019 Jan |
1 |
| 13 |
30973909 | Expression of Concern: Antitumor Activity of Sorafenib in Human Cancer Cell Lines with Acquired Resistance to EGFR and VEGFR Tyrosine Kinase Inhibitors. | 2019 |
1 |
| 14 |
30980868 | KIAA1199 promotes sorafenib tolerance and the metastasis of hepatocellular carcinoma by activating the EGF/EGFR-dependent epithelial-mesenchymal transition program. | 2019 Jul 10 |
1 |
| 15 |
31059070 | Fingolimod sensitizes EGFR wild‑type non‑small cell lung cancer cells to lapatinib or sorafenib and induces cell cycle arrest. | 2019 Jul |
1 |
| 16 |
31465134 | Activation of EGFR-KLF4 positive feedback loop results in acquired resistance to sorafenib in hepatocellular carcinoma. | 2019 Nov |
1 |
| 17 |
29251017 | Synthesis and biological evaluation of 2-styrylquinolines as antitumour agents and EGFR kinase inhibitors: molecular docking study. | 2018 Dec |
1 |
| 18 |
29514844 | COX-2/PGE2 Axis Regulates HIF2α Activity to Promote Hepatocellular Carcinoma Hypoxic Response and Reduce the Sensitivity of Sorafenib Treatment. | 2018 Jul 1 |
2 |
| 19 |
29552141 | Synergistic antitumor activity of low-dose c-Met tyrosine kinase inhibitor and sorafenib on human non-small cell lung cancer cells. | 2018 Apr |
2 |
| 20 |
30272354 | Capsaicin and sorafenib combination treatment exerts synergistic anti‑hepatocellular carcinoma activity by suppressing EGFR and PI3K/Akt/mTOR signaling. | 2018 Dec |
1 |
| 21 |
27914862 | Neurotensin regulation induces overexpression and activation of EGFR in HCC and restores response to erlotinib and sorafenib. | 2017 Mar 1 |
2 |
| 22 |
28502299 | [Tumor-associated macrophages promote the proliferation and migration as well as invasion of sorafenib-resistant hepatocellular carcinoma cells]. | 2017 May |
4 |
| 23 |
29295519 | Design and Discovery of Quinazoline- and Thiourea-Containing Sorafenib Analogs as EGFR and VEGFR-2 Dual TK Inhibitors. | 2017 Dec 23 |
2 |
| 24 |
26898607 | A multicenter phase II study of sorafenib in combination with erlotinib in patients with advanced non-small cell lung cancer (KCSG-0806). | 2016 Mar |
3 |
| 25 |
27015562 | [Pemetrexed + Sorafenib] lethality is increased by inhibition of ERBB1/2/3-PI3K-NFκB compensatory survival signaling. | 2016 Apr 26 |
4 |
| 26 |
27090797 | HDAC6-mediated EGFR stabilization and activation restrict cell response to sorafenib in non-small cell lung cancer cells. | 2016 May |
6 |
| 27 |
24911215 | Sorafenib/regorafenib and lapatinib interact to kill CNS tumor cells. | 2015 Jan |
1 |
| 28 |
25861837 | A Phase II Study of Sorafenib Combined With Cetuximab in EGFR-Expressing, KRAS-Mutated Metastatic Colorectal Cancer. | 2015 Sep |
2 |
| 29 |
25870375 | A novel approach using sorafenib in alpha fetoprotein-producing hepatoid adenocarcinoma of the lung. | 2015 Apr |
1 |
| 30 |
24380851 | New biological perspectives for the improvement of the efficacy of sorafenib in hepatocellular carcinoma. | 2014 May 1 |
2 |
| 31 |
24440279 | A multicenter phase II study of sorafenib monotherapy in clinically selected patients with advanced lung adenocarcinoma after failure of EGFR-TKI therapy (Chinese Thoracic Oncology Group, CTONG 0805). | 2014 Mar |
2 |
| 32 |
24486412 | Upregulation of HIF-2α induced by sorafenib contributes to the resistance by activating the TGF-α/EGFR pathway in hepatocellular carcinoma cells. | 2014 May |
6 |
| 33 |
24591842 | Cyclooxygenase-2 inhibitor is a robust enhancer of anticancer agents against hepatocellular carcinoma multicellular spheroids. | 2014 |
1 |
| 34 |
24736071 | Signal transducer and activator of transcription 3 as molecular therapy for non-small-cell lung cancer. | 2014 Apr |
2 |
| 35 |
25551444 | NSK-01105, a novel sorafenib derivative, inhibits human prostate tumor growth via suppression of VEGFR2/EGFR-mediated angiogenesis. | 2014 |
1 |
| 36 |
23228386 | Dietary supplement hymecromone and sorafenib: a novel combination for the control of renal cell carcinoma. | 2013 Jul |
1 |
| 37 |
23255896 | Sorafenib combined with gemcitabine in EGFR-TKI-resistant human lung cancer cells. | 2013 Jan |
4 |
| 38 |
23420122 | Synergistic interaction between sorafenib and gemcitabine in EGFR-TKI-sensitive and EGFR-TKI-resistant human lung cancer cell lines. | 2013 Feb |
7 |
| 39 |
23908594 | Flavopiridol synergizes with sorafenib to induce cytotoxicity and potentiate antitumorigenic activity in EGFR/HER-2 and mutant RAS/RAF breast cancer model systems. | 2013 Aug |
1 |
| 40 |
24166906 | Comprehensive biomarker analysis and final efficacy results of sorafenib in the BATTLE trial. | 2013 Dec 15 |
2 |
| 41 |
22414764 | Epidermal growth factor receptor and HER-3 restrict cell response to sorafenib in hepatocellular carcinoma cells. | 2012 Jul |
6 |
| 42 |
22514082 | EGFR activation is a potential determinant of primary resistance of hepatocellular carcinoma cells to sorafenib. | 2012 Dec 15 |
7 |
| 43 |
22783588 | The inhibition of the pemetrexed-activated MAPK pathway via sorafenib is involved in the synergistic mechanism of sorafenib subsequent potentiation of pemetrexed cytotoxicity in EGFR TKI-resistant cell lines. | 2012 |
3 |
| 44 |
21576636 | Randomized, double-blind, placebo-controlled, phase II trial of sorafenib and erlotinib or erlotinib alone in previously treated advanced non-small-cell lung cancer. | 2011 Jun 20 |
4 |
| 45 |
22147992 | Novel EGFR-TK inhibitor EKB-569 inhibits hepatocellular carcinoma cell proliferation by AKT and MAPK pathways. | 2011 Dec |
2 |
| 46 |
22174910 | Antitumor activity of sorafenib in human cancer cell lines with acquired resistance to EGFR and VEGFR tyrosine kinase inhibitors. | 2011 |
3 |
| 47 |
20395213 | A multicenter phase II study of erlotinib and sorafenib in chemotherapy-naive patients with advanced non-small cell lung cancer. | 2010 Jun 1 |
1 |
| 48 |
20502062 | Hepatoid adenocarcinoma - review of the literature illustrated by a rare case originating in the peritoneal cavity. | 2010 |
1 |
| 49 |
20810384 | Synergistic antitumor activity of sorafenib in combination with epidermal growth factor receptor inhibitors in colorectal and lung cancer cells. | 2010 Oct 15 |
1 |
| 50 |
20829129 | A combined A431 cell membrane chromatography and online high performance liquid chromatography/mass spectrometry method for screening compounds from total alkaloid of Radix Caulophylli acting on the human EGFR. | 2010 Oct 15 |
1 |